12:00 AM
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AV-101: Phase I data

A double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 46 healthy volunteers showed that once-daily 360, 1,080 and 1,440 mg doses of oral AV-101 for 14 days were well tolerated with "favorable" bioavailability and pharmacokinetics. In 2010,...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >